Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-labeled, randomized, crossover, single-dose study in healthy male Participants to evaluate the pharmacokinetics, safety, and tolerability of stable isotopologs of atazanavir (ATV), administered as single agents or as combinations of two isotopologs, with a pharmacokinetic comparison to Reyataz

Next Previous
Trial Profile

An open-labeled, randomized, crossover, single-dose study in healthy male Participants to evaluate the pharmacokinetics, safety, and tolerability of stable isotopologs of atazanavir (ATV), administered as single agents or as combinations of two isotopologs, with a pharmacokinetic comparison to Reyataz

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir (Primary) ; C 10276 (Primary) ; CTP 518 (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Concert Pharmaceuticals

Most Recent Events

  • 24 Oct 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01458769).
  • 24 Oct 2011 Additional lead trial investigator and actual patient no. added 47 as reported by ClinicalTrials.gov.
  • 24 Oct 2011 Planned End Date added to 1 Apr 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top